For years, managing moderate-to-severe plaque psoriasis was about managing expectations. We aimed for ‘improvement’. Today we’re aiming for remission.
The shift toward IL-23 inhibitors like Ilumya represents a major leap in precision medicine. By selectively targeting the p19 subunit of the IL-23 cytokine, we aren’t just “quieting” the immune system- we are interrupting the inflammatory cycle at its source.
What makes this a game-changer in 2025?
- Sustainability: Recent data shows significantly skin clearance (PASI 90/100) can be maintained for up to 5 years.
- Minimal Burden: After starter doses, maintenance is just 4 doses a year. That’s 4 days of treatment for 361 days of living.
- Precision: It treats high-impact areas like the scalp and nails, historically some of the most “stubborn” regions to clear.
As the definition of “remission” evolves toward a Body Surface Area (BSA) of 0%, our tools are finally catching up to our goals.
MBH/PS